Europe’s pharma industry saw a drop of 3.9% in deal activity during February 2019, when compared with the last 12-month average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 27 pharma industry deals worth $1.06bn were announced for the region in February 2019, against the 12-month average of 26 deals.

Of all the deal types, venture financing saw most activity in February 2019 with 14 transactions, representing a 51.9% share for the region.

In second place was M&A with eight deals, followed by private equity deals with five transactions, respectively capturing a 29.6% and 18.5% share of the overall deal activity for the month.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In terms of value of deals, M&A was the leading category in Europe’s pharma industry with $521.34m, while venture financing and private equity deals totalled $355.07m and $181.23m, respectively.

Europe pharma industry deals in February 2019: Top deals

The top five pharma deals accounted for 86.7% of the overall value during February 2019.

The combined value of the top five pharma deals stood at $917.27m, against the overall value of $1.06bn recorded for the month. The top announced pharma deal tracked by GlobalData in February 2019 was Charles River Laboratories International‘s $510m acquisition of CiToxLAB Group.

In second place was the $179.86m venture financing of Arvelle Therapeutics by BRV Capital Management, Andera Partners, H.I.G. BioHealth Partners, Life Sciences Partners and NovaQuest Capital Management and in third place was RoundTable Healthcare Management and Signet Healthcare Partners’ $155m private equity deal with Moberg Pharma North America and MPJ OTC.

The $37.4m venture financing of Hookipa Biotech by Redmile Group, Samsara BioCapital and Invus Group and Syncona and Novartis Venture Fund’s venture financing of Anaveon for $35m held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.